Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity

Thomas H. Pillow(Genesys (United States)), Peter S. Dragovich(Pfizer (United States)), Shang‐Fan Yu(Genesys (United States)), Tracy Kleinheinz(Genesys (United States)), Brandon Latifi(Genesys (United States)), Isabel Figueroa(Merck & Co., Inc., Rahway, NJ, USA (United States)), Karen E. Gascoigne(University of Manchester), Jack Sadowsky(Genesys (United States)), Cong Wu(Fujian University of Traditional Chinese Medicine), Chun Sing Li(WuXi AppTec (China)), Rebecca K. Rowntree(Genesys (United States)), Donglu Zhang(Acentech (United States)), Pragya Adhikari(Genesys (United States)), Douglas D. Leipold(Genesys (United States)), Katherine R. Kozak(University of California, Los Angeles), Gauri Deshmukh(Yashwantrao Chavan Maharashtra Open University), Zijin Xu(WuXi AppTec (China)), Aimee O’Donohue(Genesys (United States)), Amrita V. Kamath(Bristol-Myers Squibb (United States)), Hongyan Zhang(Tianjin University), Xinxin Wang(Handan College), Jinhua Chen(Hunan University), Hui Yao(Jinan University), Xiaoyu Zhu(WuXi AppTec (China)), Hao Zhou(Institute of Chemical Industry of Forest Products), Ruina Li(Genesys (United States)), Susan Kaufman(Genesys (United States)), Robert A. Blake(Exelixis (United States)), John Wai(WuXi AppTec (China)), Richard Zang(Genesys (United States)), Geoffrey Del Rosario(Genesys (United States)), Melinda M. Mulvihill(Genesys (United States))
ChemMedChem
October 31, 2019
Cited by 193


Related Papers